Abstract
The availability of the analogs cisplatin and carboplatin has sparked considerable controversy as to the relative merits of the two agents. A number of randomized clinical trials have been done that address this issue. As expected, most of these trials have been done in the tumor types that are the most responsive to these agents, ovarian and testis cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams, M., Kerby, I. J., et al. (1989). A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28:57.
Alberts, D. S., Green, S., et al. (1992). Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706.
Bajorin, D. F., Sarosdy, M.F., et al. (1993). Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598.
Bokemeyer, Harstrick, C. A., et al. (1994). The use of carboplatin in malignant germ cell tumours. EurJ Cancer 30A: 721.
Childs, W. J., Nicholls. E. J., et al. (1992). The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 3:29.
Conti, P. F., Bruzzone, M., et al. (1991). Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III–IV ovarian carcinoma. J Clin Oncol 9:658.
Edmonson, J. H., McCormack, G.M., et al. (1989). Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III–IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst 81:1500.
Advanced Ovarian Cancer Trialists Group. (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Brit Med J 303: 884.
Horwich, A. and Sleijfer, D. (1994). Carboplatin-based chemotherapy in good prognosis metastatic non-seminoma of the testis: an interim report of an MRC/EORTC randomised trial. Proc. Leeds Germ Cell Tumour Conference (abstract).
Kattan, J., Mahjoubi, M., et al. (1993). High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. EurJ Cancer 29A: 1504.
Mangioni, C., Bolis, G., et al. (1989). Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:1464.
McGuire, W. P., Hoskins, W. J., et al. (1993). A phase III trial comparing cisplatin/Cytoxan and cisplatin/Taxol in advanced ovarian cancer. Proc Amer Soc Clin Oncol 12: 255 (abstract).
Swenerton, K., Jeffrey, J., et al. (1992). Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase IE study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718.
Taylor, A. E., Wiltshaw, E., et al. (1994). Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12: 2066–2070.
ten Bokkel Huinink, W. W., van der Berg M. E. L., et al. (1988). Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 15: 9.
Tjulandin, S. A., Garin, A. M., et al. (1993). Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 4: 663–667.
Vermorken, J. B., ten Bokkel Huinink, W. W., et al. (1993). Carboplatin versus cisplatin. Ann Oncol 4: S41.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Williams, S.D. (1996). Cisplatin and Carboplatin in Testis and Ovarian Cancer: Pro Cisplatin. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_29
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0218-4_29
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0220-7
Online ISBN: 978-1-4899-0218-4
eBook Packages: Springer Book Archive